Limited ESA Use in COVID-19 Patients Recommended
Infection with the virus that causes COVID-19, coupled with use of erythropoiesis-stimulating agents may result in additive prothrombotic effects, according to the authors.
Anemias
Molidustat Noninferior to Darbepoetin in Nondialysis CKD
In 2 Japanese trials of nondialysis patients, molidustat proved noninferior to darbepoetin alfa, an erythropoiesis-stimulating agent, in correcting and maintaining hemoglobin levels over 36 weeks.
Roxadustat Noninferior to Darbepoetin in Treating Renal Anemia
In separate active comparator studies, roxadustat achieved hemoglobin correction in CKD patients and maintained hemoglobin within target range in hemodialysis patients at least as well as darbepoetin alfa over 24 weeks.
No Ophthalmic Effects From Roxadustat Short Term
In a study of patients on dialysis, investigators found no higher risk for retinal hemorrhages and other ophthalmic problems among roxadustat-treated patients compared with patients receiving darbepoetin alfa.
Most Teens Recover Iron Stores One Year After Whole Blood Donation
Less than half of blood donors with low ferritin at index achieved adequate stores within 12 months.
Erythropoietin Resistance, Elevated MACE Risk Common in Renal Anemia
In a Swedish real-world study, dialysis and nondialysis patients with high erythropoietin resistance index values had increased risk for major adverse cardiovascular events.
Vadadustat Noninferior to Darbepoetin Alfa for Anemia in Patients With Dialysis-Dependent CKD
The studies compared the efficacy and safety of vadadustat to darbepoetin alfa in adult patients on dialysis with anemia due to CKD.
High-Dose vs Low-Dose IV Iron Does Not Raise Infection Risk in Hemodialysis Patients
Patients on hemodialysis who received high-dose had similar rates of infection and rates of hospitalization for infection compared with those treated with low-dose IV iron, a secondary analysis of the PIVOTAL trial revealed.
Amid COVID-19 Crisis, Blood Donor Restrictions Eased
FDA has changed abstinence period required for gay and bisexual blood donors from 12 months to three months
Triferic AVNU Approved for Iron Replacement and Hemoglobin Maintenance in Dialysis Patients
The FDA has approved the New Drug Application for Triferic AVNU®.
-
Loading...
-
Loading...
Next post in Anemia
